Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathway

Bibliography

• BRODEUR GM, PRITCHARD J, BERTHOLD F et al.: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. (1993) 11(8):1466-1477.
   PubMed Web of Science ®Google Scholar
• NAKAGAWARA A, ARIMA-NAKAGAWARA M, SCAVARDA NJ, AZAR CG, CANTOR AB, BRODEUR GM: Association between high levels of expression o the TRK gene and favorable outcome in human neuroblastoma. N. Engl. J. Med. (1993) 328:847-854.
   PubMed Web of Science ®Google Scholar
• BRODEUR GM, MARIS JM, YAMASHIRO DJ, HOGARTY MD, WHITE PS: Biology and genetics of human neuroblastoma. J. Pediatr. Hematol. Oncol. (1997) 19:93-101.
   PubMed Web of Science ®Google Scholar
• LEDOUARIN N: The Neural Crest. London: Cambridge University Press (1981).
   Google Scholar
• ISRAEL MA, THIELE CJ: Tumor cell lines of the peripheral nervous system. In: Atlas of Human Tumor Cell Lines. Hay RJ, Park JG, Gazdar A (Eds.), Academic Press, Inc., San Diego, USA (1994).
   Google Scholar
• SMEYNE RJ, KLEIN R, SCHNAPP A et al.: Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature (1994) 368(6468):246-249.
   PubMed Web of Science ®Google Scholar
• MILLER FS, KAPLAN DR: Neurotrophin signaling pathways regulating neuronal apoptosis. Cell Mol. Life Sci. (2001) 58(8):1045-1053.
   PubMed Web of Science ®Google Scholar
• GLEBOVA NO, GINTY DD: Growth and survival signals controlling sympathetic nervous system development. Annu. Rev. Neurosci. (2005) 28:191-222.
   PubMed Web of Science ®Google Scholar
• STRAUB JA, SHOLLER GL, NISHI R: Embryonic sympathoblasts transiently express TrkB in vivo and proliferate in response to brain-derived neurotrophic factor in vitro. BMC Dev. Biol. (2007) 7:10-23.
   PubMedGoogle Scholar
• BIREREN SJ, LO L, ANDRSON DJ: Sympathetic neuroblasts undergo a developmental switch in trophic dependence. Development (1993) 119(3):597-610.
   PubMedGoogle Scholar
• BRODEUR GM: Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer (2003) 3(3):203-216.
   PubMed Web of Science ®Google Scholar
• ACHESON A, CONOVER JC, FANDL JP et al.: A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature (1995) 374(6521):450-453.
   PubMed Web of Science ®Google Scholar
• CHEN B, DOWLATSHAHI D, MACQUEEN GM, WANG JF, YOUNG LT: Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry (2001) 50(4):260-265.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO K, WADA RK, YAMASHIRO JM, KAPLAN DR, THIELE CJ: Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res. (1995) 55(8):1798-1806.
   PubMed Web of Science ®Google Scholar
• SCALA S, WOSIKOWSKI K, GIANNAKAKOU P et al.: Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res. (1996) 56(16):3737-3742.
   PubMed Web of Science ®Google Scholar
• MIDDLEMAS DS, KIHL BK, MOODY NM: Brain derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents. J. Neurooncol. (1999) 45(1):27-36.
   PubMedGoogle Scholar
• MIDDLEMAS DS, KIHL BK, ZHOU J, ZHU X: Brain-derived neurotrophic factor promotes survival and chemoprotection of human neuroblastoma cells. J. Biol. Chem. (1999) 274(23):16451-16460.
   PubMed Web of Science ®Google Scholar
• ENCINAS M, IGLESIAS M, LLECHA N, COMELLA JX: Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J. Neurochem. (1999) 73(4):1409-1421.
   PubMed Web of Science ®Google Scholar
• JABOIN J, KIM CJ, KAPLAN DR, THIELE CJ: Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res. (2002) 62(22):6756-6763.
   PubMed Web of Science ®Google Scholar
• JABOIN J, HONG A, KIM CJ, THIELE CJ: Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma. Cancer Lett. (2003) 193(1):1009-1014.
   Google Scholar
• PATAPOUTIAN A, REICHARDT LF: Trk receptors:mediators of neurotrophin action. Curr. Opin. Neurobiol. (2001) 11(3):272-280.
   PubMed Web of Science ®Google Scholar
• HO R, EGGERT A, HISHIKI T et al.: Resistance to chemotherapy mediated by TrkB in neuroblastoma. Cancer Res. (2002) 62(22):6462-6466.
   PubMed Web of Science ®Google Scholar
• EVANS AE, KISSELBACH KD, LIU X et al.: Effect of CEP-751(KT-6587) on neuroblastoma xenografts expressing TrkB. Med. Pediatr. Oncol. (2001) 36(1):181-184.
   PubMedGoogle Scholar
• EVANS AE, KISSELBACH KD, YAMASHIRO DJ et al.: Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin. Cancer Res. (1999) 5(11):3594-3602.
   PubMed Web of Science ®Google Scholar
• JIANG Z, YU PH: Involvement of extracellular signal-regulated kinases 1/2 and (phosphoinositide 3-kinase)/Akt signal pathways in acquired resistance against neurotoxin of 6-hydroxydopamine in SH-SY5Y cells following cell–cell interaction with astrocytes. Neuroscience (2005) 133(2):405-411.
   PubMedGoogle Scholar
• DATTA SR, BRUNET A, GREENBERG ME: Cellular survival: a play in three Akts. Genes Dev. (1999) 13:2905-2927.
   PubMed Web of Science ®Google Scholar
• ROSEN N, SHE QB: Akt and cancer – is it all mTOR? Cancer Cell (2006) 10(4):254-256.
   PubMed Web of Science ®Google Scholar
• DUDEK H, DATTA SR, FRANKE TF et al.: Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (1997) 275(5300):661-665.
   PubMed Web of Science ®Google Scholar
• CROWDER RJ, FREEMAN RS: The survival of sympathetic neurons promoted by potassium depolarization, but not by cyclic AMP, requires phosphatidylinositol 3-kinase and Akt. J. Neurochem. (1999) 73(2):466-475.
   PubMedGoogle Scholar
• CROWDER RJ, FREEMAN RS: Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. J. Neurosci. (1998) 18(8):2933-2943.
   PubMed Web of Science ®Google Scholar
• GOSWAMI R, KILKUS J, DAWSON SA, DAWSON G: Overexpression of Akt (protein kinase B) confers protection against apoptosis and prevents formation of ceramide in response to pro-apoptotic stimuli. J. Neurosci. Res. (1999) 57(6):884-893.
   PubMed Web of Science ®Google Scholar
• SALINAS M, MARTIN D, ALVAREZ A, CUADRADO A: Akt1/PKBα protects PC12 cells against the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium and reduces the levels of oxygen-free radicals. Mol. Cell. Neurosci. (2001) 17(1):67-77.
   PubMedGoogle Scholar
• HUMBERT S, BRYSON EA, CORDELIERES FP et al.: The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell (2002) 2(6):831-837.
   PubMed Web of Science ®Google Scholar
• DHANDAPANI KM, WADE FM, MAHESH VB, BRANN DW: Astrocyte-derived transforming growth factor-β mediates the neuroprotective effects of 17β-estradiol: involvement of nonclassical genomic signaling pathways. Endocrinology (2005) 146(6):2749-2759.
   PubMedGoogle Scholar
• LI Z, JABOIN J, DENNIS PA, THIELE CJ: Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death. Cancer Res. (2005) 65(6):2070-2075.
   PubMedGoogle Scholar
• TANAKA M, GROSSMAN HB: In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther. (2003) 10(19):1636-4162.
   PubMedGoogle Scholar
• O'GORMAN DM, MCKENNA SL, MCGAHON AJ, KNOX KA, COTTER TG: Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia (2000) 14(4):602-611.
   PubMed Web of Science ®Google Scholar
• NG SS, TSAO MS, NICKLEE T, HEDLEY DW: Wortmannin inhibits Pkb/Akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res. (2001) 7(10):3269-3275.
   PubMed Web of Science ®Google Scholar
• TORETSKY JA, THAKAR M, ESKENAZI AE, FRANTZ CN: Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. Cancer Res. (1999) 59(22):5745-5750.
   PubMed Web of Science ®Google Scholar
• BROGNARD J, CLARK AS, NI Y, DENNIS PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. (2001) 61(10):3986-3997.
   PubMed Web of Science ®Google Scholar
• JIN ZH, KUROSU T, YAMAGUCHI M, ARAI A, MIURA O: Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. Oncogene (2005) 24(12):1973-1981.
   PubMedGoogle Scholar
• MEYER GE, CHESLER L, LIU D et al.: Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. J. Cell. Biochem. (2007) [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• GUERREIRO AS, BOLLER D, SHALABY T, GROTZER MA, ARCARO A: Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition. Int. J. Cancer (2006) 119(11):2527-2538.
   PubMed Web of Science ®Google Scholar
• CHIU B, MIRKIN B, MADONNA MB: Mitogenic and apoptotic actions of epidermal growth factor on neuroblastoma cells are concentration-dependent. J. Surg. Res. (2006) 135(2):209-212.
   PubMed Web of Science ®Google Scholar
• HO R, MINTURN JE, HISHIKI T et al.: Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res. (2005) 6521):9868-9875.
   PubMedGoogle Scholar
• SERVIDEI T, RICCARDI A, SANGUINETTI M, DOMINICI C, RICCARDI R: Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J. Cell. Physiol. (2006) 208(1):220-228.
   PubMed Web of Science ®Google Scholar
• KIM NH, KIM K, PARK WS, SON HS, BAE Y: PKB/Akt inhibits ceramide-induced apoptosis in neuroblastoma cells by blocking apoptosis-inducing factor (AIF) translocation. J. Cell. Biochem. (2007) [Epub ahead of print].
   Google Scholar
• SHANKAR SL, KRUPSKI M, PARASHAR B et al.: UCN-01 alters phosphorylation of Akt and GSK3β and induces apoptosis in six independent human neuroblastoma cell lines. J. Neurochem. (2004) 90(3):702-711.
   PubMedGoogle Scholar
• MOOKHERJEE P, QUINTANILLA R, ROH MS, ZMIJEWSKA AA, JOPE RS, JOHNSON GV: Mitochondrial-targeted active Akt protects SH-SY5Y neuroblastoma cells from staurosporine-induced apoptotic cell death. Cell. Biochem. (2007) 102(1):196-210.
   PubMedGoogle Scholar
• KHAN T, HIXON JA, STAUFFER JK et al.: Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma. J. Natl. Cancer Inst. (2006) 98(3):190-202.
   PubMed Web of Science ®Google Scholar
• LIU XH, YU EZ, LI YY, ROLLWAGEN FM, KAGAN E: RNA interference targeting Akt promotes apoptosis in hypoxia-exposed human neuroblastoma cells. Brain Res. (2006) 1070(1):24-30.
   PubMedGoogle Scholar
• OPEL D, POREMBA C, SIMON T, DEBATIN KM, FULDA S: Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res. (2007) 67(2):735-745.
   PubMed Web of Science ®Google Scholar
• VIVANCO I, SAWYERS CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer (2002) 2(7):489-501.
   PubMed Web of Science ®Google Scholar
• ALESSI DR, JAMES SR, DOWNES CP et al.: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr. Biol. (1997) 7(4):261-269.
   PubMed Web of Science ®Google Scholar
• COFFER PJ, WOODGETT JR: Molecular cloning and characterization of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur. J. Biochem. (1991) 201(2):475-481.
   PubMedGoogle Scholar
• CASTILLO SS, BROGNARD J, PETUKHOV PA et al.: Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res. (2004) 64(8):2782-2792.
   PubMedGoogle Scholar
• GILLS JJ, DENNIS PA: The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin. Investig. Drugs (2004) 13(7):787-797.
   PubMed Web of Science ®Google Scholar
• GILLS JJ, HOLBECK S, HOLLINGSHEAD M, HEWITT SM, KOZIKOWSKI AP, DENNIS PA: Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol. Cancer Ther. (2006) 5(3):713-722.
   PubMed Web of Science ®Google Scholar
• BARNETT SF, BILODEAU MT, LINDSLEY CW: The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr. Top. Med. Chem. (2005) 5(2):109-125.
   PubMed Web of Science ®Google Scholar
• RUITER GA, ZERP SF, BARTELINK H, VAN BLITTERSWIJK WJ, VERHEIJ M: Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs (2003) 14(2):167-173.
   PubMed Web of Science ®Google Scholar
• KONDAPAKA SB, SINGH SS, DASMAHAPATRA GP, SAUSVILLE EA, ROY KK: Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther. (2003) 2(11):1093-1103.
   PubMed Web of Science ®Google Scholar
• BERDEL WE, BAUSERT WR, WELTZIEN HU, MODOLELL ML, WIDMANN KH, MUNDER PG: The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma. Eur. J. Cancer (1980) 16(9):1199-1204.
   PubMed Web of Science ®Google Scholar
• VOGLER WR, BERDEL WE, GELLER RB et al.: A Phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. Adv. Exp. Med. Biol. (1996) 416:389-396.
   PubMedGoogle Scholar
• GIANTONIO BJ, DERRY C, MCALEER C, MCPHILLIPS JJ, O'DWYER PJ: Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors. Clin. Cancer Res. (2004) 10(4):1282-1288.
   PubMedGoogle Scholar
• LEONARD R, HARDY J, VAN TIENHOVEN G et al.: Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J. Clin. Oncol. (2001) 19(21):4150-4159.
   PubMed Web of Science ®Google Scholar
• VINK SR, SCHELLENS JH, VAN BLITTERSWIJK WJ, VERHEIJ M: Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest. New Drugs (2005) 23(4):279-286.
   PubMed Web of Science ®Google Scholar
• LEIGHL NB, DENT S, CLEMONS M et al.: A Phase II study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res. Treat. (2007) [Epub ahead of print].
   PubMedGoogle Scholar
• BAILEY HH, MAHONEY MR, ETTINGER DS et al.: Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer (2006) 107(10):2462-2467.
   PubMed Web of Science ®Google Scholar
• MARSH RDE W, ROCHA LIMA CM, LEVY DE, MITCHELL EP, ROWLAND KM Jr, BENSON AB III: A Phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am. J. Clin. Oncol. (2007) 30(1):26-31.
   PubMed Web of Science ®Google Scholar
• ALESSI DR, JAMES SR, DOWNES CP et al.: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr. Biol. (1997) 7(4):261-269.
   PubMed Web of Science ®Google Scholar
• STOKOE D, STEPHENS LR, COPELAND T et al.: Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science (1997) 277(5325):567-570.
   PubMed Web of Science ®Google Scholar
• BARNETT SF, DEFEO-JONES D, FU S et al.: Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. (2005) 385(Part 2):399-408.
   PubMed Web of Science ®Google Scholar
• DEFEO-JONES D, BARNETT SF, FU S et al.: Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol. Cancer Ther. (2005) 4(2):271-279.
   PubMed Web of Science ®Google Scholar
• ZHAO Z, LEISTER WH, ROBINSON RG et al.: Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg. Med. Chem. Lett. (2005) 15(4):905-909.
   PubMed Web of Science ®Google Scholar
• LINDSLEY CW, ZHAO Z, LEISTER WH et al.: Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. (2005) 15(3):761-764.
   PubMed Web of Science ®Google Scholar
• KIM S, KANG J, HU W, EVERS BM, CHUNG DH: Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int. J. Cancer (2003) 1033):352-359.
   PubMed Web of Science ®Google Scholar
• KANG J, KAMAL A, BURROWS FJ, EVERS BM, CHUNG DH: Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors. Anticancer Res. (2006) 26(3A):1903-1908.
   PubMed Web of Science ®Google Scholar
• BAGATELL R, BELIAKOFF J, DAVID CL, MARRON MT, WHITESELL L: Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int. J. Cancer (2005) 113(2):179-188.
   PubMed Web of Science ®Google Scholar
• SOLAR P, HORVATH V, KLEBAN J et al.: Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. Neoplasma (2007) 54(2):127-130.
   PubMedGoogle Scholar
• NOWAKOWSKI GS, MCCOLLUM AK, AMES MM et al.: A Phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin. Cancer Res. (2006) 12(20 Part 1):6087-6093.
   PubMed Web of Science ®Google Scholar
• VASTAG B: HSP-90 inhibitors promise to complement cancer therapies. Nat. Biotechnol. (2006) 24(11):1307.
   PubMedGoogle Scholar
• DEEKS SG, SMITH M, HOLODNIY M, KAHN JO: HIV-1 protease inhibitors. A review for clinicians. AMA (1997) 277(2):145-153.
   PubMed Web of Science ®Google Scholar
• CARR A, SAMARAS K, THORISDOTTIR A, KAUFMANN GR, CHISHOLM DJ, COOPER DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet (1999) 353(9170):2093-2099.
   PubMed Web of Science ®Google Scholar
• IKEZOE T, DAAR ES, HISATAKE J, TAGUCHI H, KOEFFLER HP: HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood (2000) 96(10):3553-3559.
   PubMed Web of Science ®Google Scholar
• DEWAN MZ, UCHIHARA JN, TERASHIMA K et al.: Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood (2006) 107(2):716-724.
   PubMedGoogle Scholar
• SGADARI C, BARILLARI G, TOSCHI E et al.: HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat. Med. (2002) 8(3):225-232.
   PubMed Web of Science ®Google Scholar
• YANG Y, IKEZOE T, TAKEUCHI T et al.: HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci. (2005) 96(7):425-433.
   PubMedGoogle Scholar
• GUPTA AK, CERNIGLIA GJ, MICK R, MCKENNA WG, MUSCHEL RJ: HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res. (2005) 65(18):8256-8265.
   PubMed Web of Science ®Google Scholar
• YANG Y, IKEZOE T, NISHIOKA C et al.: NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. Br. J. Cancer (2006) 95(12):1653-1662.
   PubMed Web of Science ®Google Scholar